Thanks! You've successfully subscribed to the BONEZONE®/OMTEC® Monthly eNewsletter!

Please take a moment to tell us more about yourself and help us keep unwanted emails out of your inbox.

Choose one or more mailing lists:
BONEZONE/OMTEC Monthly eNewsletter
OMTEC Conference Updates
Advertising/Sponsorship Opportunities
Exhibiting Opportunities
* Indicates a required field.

Agluna Treated Devices Significantly Reduce Infection Rates

Results of a retrospective review of infection rates associated with orthopaedic limb salvage devices treated with Accentus Medical's Agluna® surface technology revealed an overall reduction in post-op infection rates, from 22.4% in control to 11.8% with treated implants. The team also concluded a range of other beneficial clinical outcomes:

• Success rates with debridement, antibiotics and implant retention increased from 31.6% (control ) to 70% (Agluna)

• Persistent periprosthetic infection necessitating device removal, amputation or chronic antibiotics suppression reduced from 15.3% (contro) to 3.5% (Agluna)

• Post-op infection in patients with intraoperative positive cultures reduced from 40% (control) to 13.3% (Agluna)

• Success rates with two-stage revisions increased from 57.1% (control) to 85% (Agluna)


Agluna uses anti-microbial properties of silver ions to prevent device-related infection. The technology is supplied by Accentus Medical under licence to Stanmore Implants on its custom patient specific limb salvage devices. (Source: Accentus Medical)